image credit: Unsplash

Novartis works on pan-coronavirus pill, eyes 2022 human testing

December 9, 2021


Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID: Now, however, it’s taking its massive R&D budget and targeting not just the current pandemic, but all coronaviruses.

The U.S.-Swiss pharma is working on a main protease (Mpro) inhibitor drug, an early field of study that has been yielding some very preclinical glimmers that it can fight back against SARS-CoV-2.

But Novartis, which is in the preclinical phase for this program, has found that the main protease is not limited to just SARS-CoV-2 but rather is highly genetically conserved across many coronaviruses.

Read More on FierceBiotech